Sort
48,018 grants matching “immunotherapy”
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$713,488Yi Lin · Mayo Clinic Rochester · R01 · FY2021 · CA
Depleting exosomes to improve responses to immune therapy in HNSCC
$713,327Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2022 · DE
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
$713,250Ellis L Reinherz · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Predictive Markers in Metastatic Renal Cancer
$713,221Frederic M. Waldman · University Of California, San Francisco · R01 · FY2008 · CA
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies
$713,138John F Dipersio · Washington University · R35 · FY2025 · CA
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$713,044Ming You · Methodist Hospital Research Institute · R01 · FY2021 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$713,011Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$712,992Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Ten-Fold Resolution Boost for Magnetic Particle Imaging with Applications to Rapid, Non-Invasive Imaging of CAR-T Cell Therapies, Stroke, GI Bleeds and Pulmonary Embolisms
$712,953Steven M Conolly · University Of California Berkeley · U01 · FY2023 · EB
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
$712,871Daniel B Stetson · University Of Washington · R01 · FY2025 · CA
Molecular Allergy
$712,865Geoffrey Mueller · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Bronx-Lebanon Hospital Center Pediatric ACTU
$712,836Bronx-Lebanon Hosp Ctr (Bronx, Ny) · U01 · FY2003 · AI
Assessing the determinants of durable protective immunity in SARS-CoV-2 infected human subjects
$712,821Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2021 · AI
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
$712,811Kevan C Herold · Yale University · R01 · FY2021 · DK
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
$712,802Shabaana A. Khader · Washington University · R01 · FY2017 · AI
NCI Pediatric In Vivo Testing Program: Neuroblastoma
$712,800Yael P Mosse · Children'S Hosp Of Philadelphia · U01 · FY2023 · CA
NCI Pediatric In Vivo Testing Program: Neuroblastoma
$712,800Yael P Mosse · Children'S Hosp Of Philadelphia · U01 · FY2021 · CA
NCI Pediatric In Vivo Testing Program: Neuroblastoma
$712,799Yael P Mosse · Children'S Hosp Of Philadelphia · U01 · FY2025 · CA
NCI Pediatric In Vivo Testing Program: Neuroblastoma
$712,799Yael P Mosse · Children'S Hosp Of Philadelphia · U01 · FY2024 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
$712,796Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
$712,796Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
$712,735Sarmad Sadeghi · University Of Southern California · R01 · FY2025 · CA
Safety and Efficacy of SHIV Vaccine in Macaques
$712,734University Of Kansas Medical Center · R01 · FY2003 · AI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
$712,726Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$712,726Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2022 · CA